Friedenthal Financial Buys Shares of 5,930 Biogen Inc. $BIIB

Friedenthal Financial bought a new stake in Biogen Inc. (NASDAQ:BIIB) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 5,930 shares of the biotechnology company’s stock, valued at approximately $1,087,000.

Several other large investors have also modified their holdings of the stock. Reflection Asset Management purchased a new position in Biogen in the 4th quarter valued at $25,000. WPG Advisers LLC lifted its stake in shares of Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares during the period. Accredited Wealth Management LLC increased its stake in shares of Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 185 shares during the period. First Horizon Corp purchased a new position in Biogen during the fourth quarter worth about $30,000. Finally, WFA of San Diego LLC acquired a new stake in Biogen in the second quarter valued at about $32,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

Biogen stock opened at $199.59 on Thursday. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $205.97. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The firm’s 50-day simple moving average is $192.20 and its 200 day simple moving average is $185.31. The firm has a market capitalization of $29.47 billion, a PE ratio of 21.42 and a beta of 0.20.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period last year, the firm posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities research analysts predict that Biogen Inc. will post 13.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BIIB shares. Freedom Capital raised Biogen from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Needham & Company LLC reissued a “buy” rating on shares of Biogen in a report on Thursday, June 18th. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and lifted their price target for the company from $185.00 to $225.00 in a research note on Wednesday, April 22nd. Royal Bank Of Canada upped their price objective on Biogen from $222.00 to $227.00 and gave the stock an “outperform” rating in a report on Wednesday, May 27th. Finally, HC Wainwright reiterated a “buy” rating on shares of Biogen in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Biogen currently has an average rating of “Moderate Buy” and a consensus target price of $217.37.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.